Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders (CLASP-S Trial)

Recruiting in Palo Alto (17 mi)

Overseen ByBrandon Gaudiano, PhD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Butler Hospital

No Placebo Group

Trial Summary

What is the purpose of this trial?The current project is a pilot randomized controlled trial to test the Coping Long-term with Active Suicide Program for schizophrenia-spectrum disorders (CLASP-S) for patients following a psychiatric hospitalization. Participants will be assigned to enhanced treatment as usual (ETAU) alone vs CLASP-S plus ETAU. Participants complete assessments at baseline during their psychiatric hospitalization and at 3 months (mid-treatment) and 6 months (post-treatment) following discharge. The primary aim is to assess the feasibility and acceptability of CLASP-S. The secondary aim is to estimate the effects of CLASP-S on reducing suicidal thoughts and behaviors relative to ETAU.

Eligibility Criteria

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: Coping Long-term with Active Suicide Program for SchizophreniaExperimental Treatment2 Interventions

Coping Long-term with Active Suicide Program for Schizophrenia-Spectrum Disorders (CLASP-S) includes 3 individual sessions, 1 family meeting, and 11 phone sessions with the participant and their significant other over 6 months post-hospital discharge.

Group II: Enhanced Treatment as UsualActive Control1 Intervention

Participants assigned to Enhanced Treatment as Usual (ETAU) alone will receive unrestricted routine care in the community. Assessment feedback reports will be sent to participants' community providers at baseline, 3 months, and 6 months for care coordination.